DHL Group to Invest 3.2 Trillion KRW in Life Sciences and Healthcare Logistics Over 5 Years

"Strengthening Infrastructure and Technology at All Logistics Touchpoints"
Launch of New Brand: DHL Health Logistics

The integrated logistics company DHL Group announced on the 14th that it will invest 2 billion euros (approximately 3.2 trillion KRW) in logistics for the life sciences and healthcare sectors by 2030.

Provided by DHL Group

This investment aims to achieve the life sciences and healthcare sector goals set out in the 'Strategy 2030 - Accelerating Sustainable Growth' announced last October. Half of the total investment will be allocated to the Americas, 25% to the Asia-Pacific region, and the remainder to Europe, the Middle East, and Africa (EMEA), providing integrated logistics solutions in all regions where healthcare companies operate.

DHL Group explained that the core of this investment is to strengthen infrastructure and technology at all logistics touchpoints, from storage, order processing, and distribution to global transportation and final delivery. Through this, they plan to offer customers more resilient and scalable supply chains. A significant portion of the investment will be used for ▲establishing new integrated Good Distribution Practice (GDP) certified pharmaceutical logistics hubs ▲expanding cold chain capabilities at existing facilities ▲introducing new temperature-controlled vehicles ▲improving refrigerant-based (passive) and power-based (active) packaging solutions for sustainable transportation.

As demand increases in key areas such as biopharmaceuticals, cell and gene therapy, and clinical trials, DHL Group is also investing in high-quality specialized cooling infrastructure for low-temperature and ultra-low-temperature transportation. They plan to introduce state-of-the-art information technology (IT) systems that monitor the entire transportation process in real time to preserve product quality, comply with regulations, and ensure trust for healthcare providers and patients.

Alongside this, DHL Group has launched a new divisional brand, 'DHL Health Logistics,' which integrates the expertise of each business unit in the life sciences and healthcare sectors. The aim is to provide customers with a seamless and consistent end-to-end (E2E) supply chain experience and simplify complex cross-border supply chain management based on high-quality services. In particular, it targets reflecting the needs of biopharmaceutical and medical customers who require solutions beyond traditional cold chain logistics services.

Oscar de Bok, CEO of DHL Supply Chain, said, "Strategic investment in the life sciences and healthcare sectors stems from our mission to deliver essential and sometimes life-saving products to those in need." He added, "DHL Group is building high-quality integrated logistics solutions as innovative and reliable as the products our customers create." He further stated, "Our goal is to ensure that patients worldwide receive the treatments they need at the right time and in a completely trustworthy environment."

Meanwhile, DHL Group achieved over 5 billion euros in related global sales in the life sciences and healthcare logistics sector last year. They expect an additional 5 billion euros in sales growth by 2030. Currently, they operate about 600 dedicated life sciences and healthcare logistics sites, hubs, and warehouses in approximately 130 countries worldwide. Recently, they acquired CRYOPDP, a specialized logistics company focused on logistics for biopharmaceuticals, cell and gene therapy, and clinical trials.